Literature DB >> 2553254

Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.

C Holm1, J M Covey, D Kerrigan, Y Pommier.   

Abstract

The cytotoxicity of topoisomerase inhibitors is thought to result from the induction of enzyme-mediated DNA breaks. The fact that these breaks reverse rapidly in cells programmed to die, led us to investigate further the cytotoxic mechanisms of topoisomerase I (camptothecin) and topoisomerase II inhibitors (VP-16 and amsacrine) in Chinese Hamster lung fibroblasts (DC3F). Exposures (30 min) to camptothecin produced limited cell killing with approximately 20% of the cells naturally resistant. This resistance was overcome by increasing the drug exposure time. Inhibition of DNA synthesis by 5-min pretreatments with aphidicolin or hydroxyurea abolished the cytotoxicity of camptothecin without changing the level of camptothecin-induced DNA breaks. A good correlation was found between the degree of DNA synthesis inhibition by aphidicolin and the reduction of camptothecin cytotoxicity. In similar experiments performed with topoisomerase II inhibitors, aphidicolin prevented only partially against VP-16- and amsacrine-induced cytotoxicities, yet had no effect upon drug-induced DNA breaks. These results indicate that the production of topoisomerase-mediated DNA breaks by antitumor drugs is not sufficient for cell killing. Instead, an interference of moving DNA replication forks with drug-stabilized topoisomerase-DNA complexes is critical for cell death. The cytotoxicity of camptothecin seemed to be completely related to this process, while that of topoisomerase II inhibitors seemed to involve additional mechanisms in DC3F cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553254

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  86 in total

1.  The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53.

Authors:  C Gobert; A Skladanowski; A K Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff.

Authors:  D Strumberg; A A Pilon; M Smith; R Hickey; L Malkas; Y Pommier
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

3.  A cell cycle-specific requirement for the XRCC1 BRCT II domain during mammalian DNA strand break repair.

Authors:  R M Taylor; D J Moore; J Whitehouse; P Johnson; K W Caldecott
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

4.  An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.

Authors:  G Hong; K N Kreuzer
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

5.  Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status.

Authors:  Yinghui Mao; Issac R Mehl; Mark T Muller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

6.  Endonuclease cleavage of blocked replication forks: An indirect pathway of DNA damage from antitumor drug-topoisomerase complexes.

Authors:  George Hong; Kenneth N Kreuzer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-18       Impact factor: 11.205

Review 7.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

8.  Progesterone and DNA damage encourage uterine cell proliferation and decidualization through up-regulating ribonucleotide reductase 2 expression during early pregnancy in mice.

Authors:  Wei Lei; Xu-Hui Feng; Wen-Bo Deng; Hua Ni; Zhi-Rong Zhang; Bo Jia; Xin-Ling Yang; Tong-Song Wang; Ji-Long Liu; Ren-Wei Su; Xiao-Huan Liang; Qian-Rong Qi; Zeng-Ming Yang
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

9.  RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.

Authors:  S E Martin; Z-H Wu; K Gehlhaus; T L Jones; Y-W Zhang; R Guha; S Miyamoto; Y Pommier; N J Caplen
Journal:  Curr Cancer Drug Targets       Date:  2011-10       Impact factor: 3.428

10.  Induction of homologous recombination following in utero exposure to DNA-damaging agents.

Authors:  Bijal Karia; Jo Ann Martinez; Alexander J R Bishop
Journal:  DNA Repair (Amst)       Date:  2013-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.